JVM, a subsidiary of Hanmi Science specializing in automated pharmaceutical dispensing, said on the 4th that its operating profit last year was 33.3 billion won, up 8.5% from a year earlier on a preliminary basis.
Revenue for the same period rose 8.6% to 173.1 billion won, the highest ever. Net profit came in at 28.4 billion won.
Last year's sales mix by market was 50% domestic and 50% exports (17% North America, 25% Europe, 8% other), with the share of overseas sales rising from a year earlier. Investment in research and development (R&D) also expanded to 10.3 billion won, or 5.9% of sales, focusing on new product development and securing future growth drivers.
The company said growth in its flagship automated drug dispensing system (ATDPS) and its fully automated vial-type pill counting device "COUNTMATE" drove export expansion. In particular, COUNTMATE, launched last year, boosted results by increasing sales in the North American market.
JVM maintains the top market share in Korea by leading with next-generation personalized automated dispensing solutions. This year, it plans to kick off a full push in domestic and overseas markets by launching the new ATDPS DOC3 automated packaging machine.
DOC3 expands the number of manual dispensing cells from 30 to 60 to efficiently manage a wider range of medicines. It also enables automatic dispensing of half tablets and specially shaped drugs, improving both dispensing accuracy and work convenience, the company said.
In overseas markets, an upgrade of the robot arm-based pouch automated dispensing solution "MENITH" has been completed, and sales will be expanded mainly in Northern European countries such as the Netherlands and Germany. In North America, COUNTMATE's growth is also expected to accelerate.
Since being integrated into Hanmi Science in 2016, JVM has sustained stable growth based on Hanmi Group's management capabilities. Hanmi Pharmaceutical and Online Pharm handle overseas and domestic businesses, respectively, while JVM focuses on R&D and production. Hanmi Pharmaceutical currently supplies JVM equipment to 60 countries through 35 global partners.
Lee Dong-hwan said, "Last year, we sustained stable growth by enhancing customer value through innovative technology and tailored solutions," and added, "This year, we expect balanced growth across domestic and overseas markets through expanded sales of MENITH and the launch of DOC3."